Category: Oncology

Progression_Final_webBanner

The IO Revolution, Part 3 of 4: The Role of the Tumor in the Cancer Immunity Cycle

Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. Part two further examined the role of the host, and in this blog, we consider the role of the tumor in the...

/ March 9, 2017
Role_of_the_Host_Full-width

The IO Revolution, Part 2 of 4: The Role of the Host in the Cancer Immunity Cycle

Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. In the next few blogs, we will consider how each of these sources of inter-patient heterogeneity has the potential to influence the...

/ January 12, 2017
FGJJJ1 T lymphocytes and cancer cell. Coloured scanning electron micrograph (SEM) of T lymphocyte cells (smaller round cells) attached

Presidents, Rock Stars and Companion Diagnostics: 2016 Review of Immunotherapy

President Jimmy Carter announced this spring that he no longer needed treatments for the metastatic melanoma found in his brain–after treatment with pembrolizumab (Keytruda, Merck), his physicians could no longer detect the cancer. In 2016, high-profile success stories, the inclusion...

/ January 7, 2017
iorevolution_full-width

The IO Revolution, Part 1 of 4: Opportunities and Challenges

Immuno-oncology (IO) focuses on harnessing the tremendous power of the human immune system to detect and destroy cancer cells.

/ November 21, 2016